Frequent hypermethylation of p16 and p15 genes in multiple myeloma

Blood

Volumn 89, Issue 7, 1997, Pages 2500-2506

  Ng, M H L ^a   Chung, Y F ^a   Lo, K W ^a   Wickham, N W R ^a   Lee, J C K ^a   Huang, D P ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; PLASMACYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING;

EID: 0030940091     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.7.2500     Document Type: Article

References (43)

1. Hong Kong Hospital Authority: Annual statistical report of Hong Kong Registry. Hong Kong, 1993, p 23
2. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma-new biological insights and advances in therapy. Blood 73:865, 1989
3. Ferti A, Panani A, Arapakis G, Raptis S: Cytogenetic study in multiple myeloma. Cancer Genet Cytogenet 12:247, 1984
4. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B: Plasma cell karyotype in multiple myeloma. Blood 71:453, 1988
5. Dewald GW, Kyle RA, Hicks GA, Greipp PR: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380, 1985
6. Van den Berghe H: Chromosomes in plasma cell malignancies. Eur J Haematol 43:47, 1989 (suppl 51)
7. Dune BGM: Cellular and molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am 6:463, 1992
8. Barlogie B, Hoover R, Epstein J: Multiple myeloma-recent developments in molecular and cellular biology. Curr Top Microbiol Immunol 194:37, 1995
9. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G: Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 8:1280, 1994
10. Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Amiot M, Bataille R: High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 91:664, 1995
11. Santhanam U, Ray A, Sehgal PB: Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88:7605, 1991
12. Karp JE, Broder S: Molecular foundations of cancer: New targets for intervention. Nature Med 1:309, 1995
13. Serrano M, Hannon GJ, Beach D: A new regulation motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993
14. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753, 1994
15. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436, 1994
16. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Deletion of p16 and p15 gene in brain tumors. Cancer Res 54:6353, 1994
17. INK4BI. Cancer Res 56:722, 1996
18. Lo KW, Huang DP, Lau KM: p16 gene alterations in naopharyngeal carcinoma. Cancer Res 55:2039, 1995
19. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487, 1993
20. Kato J-Y, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb pnosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331, 1993
21. INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321, 1995
22. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumours in primary human hematopoietic malignancies. Blood 86:1548, 1995
23. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P: p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85:657, 1995
24. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893, 1995
25. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTS1 in human cancers. Nature Med 1:686, 1995
26. Herman JG, Merlo A, Mao L, Lapiduc RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525, 1995
27. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JKS, Lee JCK, Huang DP: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56:2721, 1996
28. Dune BGM: Plasma cell disorders: Recent advances in the biology and treatment, in Hoffbrand AV (ed): Recent Advances in Haematology, vol 5. London, UK, Churchill Livingstone, 1988, p 305
29. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842, 1975
30. Salmon SE, Wampler SB: Multiple myeloma: Quantitative staging and assessment of response with a programmable pocket calculator. Blood 49:379, 1977
31. Hussussian C, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, SheahanMD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nature Genet 8:15, 1994
32. Sill H, Aguiar RCT, Schmidt H, Hochhaus A, Goldman JM, Cross NCP: Mutational analysis of the p15 and p16 genes in acute leukaemias. Br J Haematol 92:681, 1996
33. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766, 1989
34. Jones PA: DNA methylation errors and cancer. Cancer Res 56:2463, 1996
35. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531, 1995
36. Hooper WC: The role of transforming growth factor-β in hematopoiesis. A review. Leuk Res 15:179, 1991
37. Piacibello W, Severino A, Stacchini A, Aglietta M: Differential effect of transforming growth factor β1 on the proliferation of human lymphoid and myeloid leukemia cells. Haematologica 76:460, 1991
38. Thomson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB: Expression of transforming growth factor-β1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 108:661, 1989
39. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820, 1971
40. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9:3375, 1994
41. Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, Sulfaro S, Barzan L, Boiocchi M: Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: Identification of two distinct regions of preferential loss. Cancer Res 56:1146, 1996
42. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of alleic loss on 13q in prostate cancer. Cancer Res 56:1142, 1996
43. Ritter M, de Kent E, Huhn D, Neubauer A: Detection of DNA methylation in the calcitonin gene in human leukemias using differential polymerase chain reaction. Leukemia 9:915, 1995